Journal Article

Resistance to melanoma metastases in mice selected for high acute inflammatory response

Durvanei A. Maria, Orlando G. Ribeiro, Kazumi F. Pizzocaro, Marcelo De Franco, Wafa K. Cabrera, Nancy Starobinas, Valerie Gallois, Maria Siqueira, Michel Seman and Olga M. Ibañez

in Carcinogenesis

Volume 22, issue 2, pages 337-342
Published in print February 2001 | ISSN: 0143-3334
Published online February 2001 | e-ISSN: 1460-2180 | DOI:
Resistance to melanoma metastases in mice selected for high acute inflammatory response

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


The role of innate immunity in natural resistance to tumor progression was investigated in two mouse lines, AIRmax and AIRmin, selected by bi-directional selective breeding on the basis of high or low acute inflammatory response. Compared with AIRmin, AIRmax mice were shown to be resistant to 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate-induced skin cancers and here we demonstrate that AIRmax are also able to restrain the development of metastases upon transfer of MHC compatible, incompatible or xenogeneic melanomas. An acute inflammatory response to melanoma cells was observed in AIRmax mice only, although both lines were found to mount similar specific immune responses to melanoma antigens. The genetically selected lines therefore represent a model system to analyze the positive correlation between multiple resistance to tumorigenesis and host inflammatory responsiveness.

Keywords: AIR, acute inflammatory response; CSF, colony stimulating factors; DMBA, 7,12-dimethylbenz[a]anthracene; FCS, fetal calf serum; GM, granulocyte–macrophage; NSAID, non-steroidal anti-inflammatory drug; PMN, polymorphonuclear leukocytes; TPA, 12-O-tetradecanoylphorbol-13-acetate.

Journal Article.  4524 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.